B+
Bull case
20%
Probability
Target price
$40.00
Analysis reference price unavailable
Analysis 2026-07-29 · RankAlpha Sentiment Codex
AKTS
Aktis OncologyBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Aktis has advanced two radiopharmaceutical programs into Phase 1b, has Fast Track designation for AKY-1189, and expects multiple clinical data opportunities beginning in 2027. [#SEC-8K-2026-05-11]
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +16.7.
What can break
Clinical efficacy, safety, and durability remain unproven for AKY-1189 and AKY-2519.
Momentum
76
Value
46
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.00 · Bull $40.00 · Bear $15.00Analysis 2026-07-29; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $35.41
Why
Momentum76 · Δ7d +0.7
Value46 · Δ7d 0.0
Sentiment73 · Δ7d +16.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +16.7.
Contradictions & invalidation
- • Clinical efficacy, safety, and durability remain unproven for AKY-1189 and AKY-2519.
- • Delays in enrollment, the planned second AKY-2519 Phase 1b trial, or 2027 data readouts could weaken the thesis. [#SEC-8K-2026-05-11]
- • The programs remain early-stage with unproven efficacy and safety.
Catalyst clock
2026-08-31
Post-earnings miss and insider-sale overhang
Lead driver: Sentiment · See AI snapshot
Momentum
76
9% active weight
Current posture
7d trendImproving
Δ7d
+0.7
Δ21d
+17.6
Value
46
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Sentiment
73
62% active weight
Current posture
7d trendImproving
Δ7d
+16.7
Δ21d
+3.9
Why this grade
Composite grade B. Momentum 75.6 / Value 46.5 / Sentiment 72.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-29. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-07-29 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-07-29 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.37B
Beta
-
Shares Out
55.28M
P/E (TTM) · Derived
-20.7
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
+111.4%
EPS YoY
+33.6%
Gross Margin
-
Op Margin
-
Net Debt
-$215.24M
Current Ratio
16.33
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data